YF-VAX 1 dose vial
Ended Awarded Last action
- Contract number
- SPE2D324F119Z
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $14,773
Award facts
- Contract value 100% obligated
- $14,773.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $14,773.25 to DMS Pharmaceutical Group Inc. for YF-VAX (yellow fever vaccine) in single-dose vial format. The award, issued on July 18, 2024, with an ultimate completion date of July 19, 2024, utilizes firm fixed-price pricing with no set-aside designation, allowing the woman-owned small business pharmaceutical wholesaler to compete on an unrestricted basis. DMS Pharmaceutical Group Inc., headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain, specializing in the distribution of comprehensive pharmaceutical products and medical consumables to Department of Defense facilities.
This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency through the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The parent IDC, designated contract SPE2DR, was awarded on November 13, 2025, with a $499,999,999 ceiling value and extends through December 31, 2036, positioning the company as one of multiple regional prime vendor contractors within the $30.3 billion PPV-G GEN V acquisition strategy. The IDC authorizes DLA to issue delivery orders for branded and generic prescription medications, biologics, vaccines, and medical consumables to support military healthcare operations worldwide, with the company's demonstrated performance on numerous prior awards evidencing its capability to fulfill diverse pharmaceutical requirements across the federal military medical system.
Quick answers
Who was awarded contract SPE2D324F119Z?
SPE2D324F119Z was awarded to DMS Pharmaceutical Group Inc. by Medical Supply Chain (Troop Support) on July 18, 2024.
How much is contract SPE2D324F119Z worth?
The government has obligated $14,773 on SPE2D324F119Z.
Is contract SPE2D324F119Z an order under another contract?
Yes. SPE2D324F119Z is a delivery order under SPE2D021DA002, an indefinite delivery contract.
Was contract SPE2D324F119Z competed?
The extent of competition for SPE2D324F119Z was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award